Drug manufacturer Moderna says it will begin testing a variant-specific version of its COVID-19 vaccine that would target the B1351 variant first detected in South Africa. The company says it will study the B1351 variant-specific vaccine both as a potential booster to the original COVID-19 vaccine and as a standalone for people who have not yet received a vaccine at all. It will study the outcomes of three different scenarios:A single shot of the B1351 variant-specific vaccine. A booster of the original vaccine, added to the original two-dose version. Health Canada would need to approve any booster or new vaccine against the B1351 variant before it could be administered here.

Source: CBC News February 25, 2021 00:33 UTC